Michelle Geller

837 total citations
13 papers, 466 citations indexed

About

Michelle Geller is a scholar working on Oncology, Orthopedics and Sports Medicine and Surgery. According to data from OpenAlex, Michelle Geller has authored 13 papers receiving a total of 466 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Orthopedics and Sports Medicine and 3 papers in Surgery. Recurrent topics in Michelle Geller's work include Bone health and treatments (4 papers), Lipoproteins and Cardiovascular Health (3 papers) and Bone health and osteoporosis research (3 papers). Michelle Geller is often cited by papers focused on Bone health and treatments (4 papers), Lipoproteins and Cardiovascular Health (3 papers) and Bone health and osteoporosis research (3 papers). Michelle Geller collaborates with scholars based in United States, United Kingdom and Switzerland. Michelle Geller's co-authors include Rowan T. Chlebowski, Rachel B. Wagman, Erica Rockabrand, Paul D. Miller, Michael R. McClung, Beiying Ding, Alfred K. Cheung, Munro Peacock, Richard L. Weinstein and Kevin Beaumont and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Annals of the Rheumatic Diseases.

In The Last Decade

Michelle Geller

12 papers receiving 451 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michelle Geller United States	8	153	108	102	96	84	13	466
Aviva G. Asnis-Alibozek United States	5	170 1.1×	68 0.6×	23 0.2×	158 1.6×	6 0.1×	7	489
Kate Whelan United States	5	261 1.7×	35 0.3×	25 0.2×	28 0.3×	29 0.3×	9	485
Karineh Tarpinian United States	7	277 1.8×	41 0.4×	14 0.1×	50 0.5×	7 0.1×	8	552
Marcel Fontecha United States	7	137 0.9×	104 1.0×	78 0.8×	10 0.1×	11 0.1×	11	534
Chao-Sung Chang Taiwan	14	81 0.5×	110 1.0×	15 0.1×	82 0.9×	2 0.0×	28	499
AS Coates Switzerland	8	493 3.2×	88 0.8×	35 0.3×	5 0.1×	11 0.1×	20	896
Henry Schmitt United States	9	298 1.9×	138 1.3×	89 0.9×	3 0.0×	158 1.9×	12	801
D Cirillo Italy	13	95 0.6×	185 1.7×	60 0.6×	10 0.1×	6 0.1×	30	631
C. Dittmer Germany	11	69 0.5×	45 0.4×	85 0.8×	8 0.1×	7 0.1×	24	363
Gerald M. Higa United States	13	238 1.6×	168 1.6×	68 0.7×	21 0.2×	1 0.0×	50	545

Countries citing papers authored by Michelle Geller

Since Specialization

Citations

This map shows the geographic impact of Michelle Geller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Geller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Geller more than expected).

Fields of papers citing papers by Michelle Geller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Geller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Geller. The network helps show where Michelle Geller may publish in the future.

Co-authorship network of co-authors of Michelle Geller

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Geller. A scholar is included among the top collaborators of Michelle Geller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Geller. Michelle Geller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Tóth, Peter P., Olivier Descamps, Jacques Genest, et al.. (2017). Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. Circulation. 135(19). 1819–1831. 59 indexed citations

Tóth, Peter P., Olivier Descamps, Jacques Genest, et al.. (2016). A POOLED SAFETY ANALYSIS OF OVER 6000 PATIENTS FROM DOUBLE-BLIND AND OPEN-LABEL EXTENSION STUDIES WITH EVOLOCUMAB. Journal of the American College of Cardiology. 67(13). 1865–1865. 3 indexed citations

Dent, Ricardo, C. Stephen Djedjos, Jason C. Legg, et al.. (2016). Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting. SpringerPlus. 5(1). 300–300. 20 indexed citations

Gibbs, John P., J. Greg Slatter, Ogo Egbuna, et al.. (2016). Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment. The Journal of Clinical Pharmacology. 57(4). 513–523. 19 indexed citations

Silverman, Stuart L., A. Wang, Leonard K. Cheng, et al.. (2015). Comorbidity indices for clinical trials: adaptation of two existing indices for use with the FREEDOM trial in women with postmenopausal osteoporosis. Osteoporosis International. 27(1). 75–80. 3 indexed citations

Geller, Michelle, Rachel B. Wagman, Pei‐Ran Ho, et al.. (2014). SAT0479 Early Findings from Prolia® Post-Marketing Safety Surveillance for Atypical Femoral Fracture, Osteonecrosis of the Jaw, Severe Symptomatic Hypocalcemia, and Anaphylaxis. Annals of the Rheumatic Diseases. 73. 766–767. 15 indexed citations

McClung, Michael R., E. Michael Lewiecki, Michelle Geller, et al.. (2012). Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporosis International. 24(1). 227–235. 84 indexed citations

Mellström, Dan, Jacques P. Brown, Henry G. Bone, et al.. (2012). Denosumab treatment for 6years in postmenopausal women with osteoporosis: The first 3years of the freedom extension. Bone. 50. S53–S54.

Chapurlat, Roland, Socrates E. Papapoulos, Jacques P. Brown, et al.. (2012). SAT0342 Treatment of postmenopausal women with osteoporosis for six years with denosumab: Three-year results from the freedom extension. Annals of the Rheumatic Diseases. 71. 588–588. 1 indexed citations

10.

Chlebowski, Rowan T., Garnet L. Anderson, Michelle Geller, & Nananda F. Col. (2006). Coronary Heart Disease and Stroke with Aromatase Inhibitor, Tamoxifen, and Menopausal Hormone Therapy Use. Clinical Breast Cancer. 6. S58–S64. 24 indexed citations

11.

Chlebowski, Rowan T. & Michelle Geller. (2006). Adherence to Endocrine Therapy for Breast Cancer. Oncology. 71(1-2). 1–9. 203 indexed citations

12.

Geller, Michelle & Rowan T. Chlebowski. (2003). HT and breast cancer risk. Fertility and Sterility. 80. 5–9. 5 indexed citations

13.

Beaumont, Kevin, Alfred K. Cheung, Michelle Geller, & Darrell D. Fanestil. (1983). Inhibitors of peripheral-type benzodiazepine receptors present in human urine and plasma ultrafiltrates. Life Sciences. 33(14). 1375–1384. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact